Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Lenvatinib & Hepatocellular Carcinoma (HCC), the FDA approved lenvatinib on August 16, 2018 for the first‑line treatment of patients with unresectable hepatocellular carcinoma (HCC), based on the phase III REFLECT trial versus sorafenib (1). The indication is as a single agent in adults with unresectable Hepatocellular Carcinoma (HCC) who have received no prior systemic therapy; REFLECT enrolled patients with BCLC B/C, Child‑Pugh A, unresectable/metastatic disease ineligible for locoregional therapy (1).
In [Europe](brain://QMGe2vnxW…